Compare ResMed Inc. (RMD) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Zoom Video Communications, Inc. — how do they compare? ResMed Inc. trades at $231.16 (market cap $31.89B), while Zoom Video Communications, Inc. trades at $97.16 (market cap $27.62B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Zoom Video Communications, Inc. for 92 Days on average.
| RMD | ZM | |
|---|---|---|
Market Cap | $31.89B | $27.62B |
Volume | 618,314 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $277.88 | $111.88 |
52-Week Low | $182.82 | $72.72 |
Typical Hold Time | 51 Days | 92 Days |
Enterprise Value | $31.24B | $20.43B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Zoom Communications (ZM) trades at $96.20, up 1.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $118.08. The company reported strong earnings beats in Q1 and Q2 2026, with net income reaching $1.01 billion in 2025 and a robust net income margin of 65.19%. Recent news highlights AI-driven product launches and board appointments, signaling strategic growth initiatives.
The outlook for ZM is positive, supported by solid profitability and Wall Street's buy ratings, but risks include competitive pressures and reliance on international sales. The stock's current valuation metrics, such as a P/E of 8.79, suggest potential upside if earnings growth continues, though investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
